Actively Recruiting
Exploring New Biological Markers in ALS and Frontotemporal Dementia Using Advanced Tissue Analysis and AI
Led by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Updated on 2026-03-30
230
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating the ALSFTD disease spectrum, which includes amyotrophic lateral sclerosis ALS and frontotemporal dementia FTD. These two conditions share clinical, genetic, and pathological features and may even occur together in some patients. Diagnosis mainly depends on clinical symptoms, making it challenging. This study aims to discover new biological markers, called biosignatures, to improve diagnosis, patient classification, and monitoring of disease progression using advanced methods and multidisciplinary expertise.
CONDITIONS
Brief Title
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
Research Team
F
Fabio Moda, phd
A
Arianna Ciullini, phd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
